salbutamol "teva" 1mg/ml inhalationsvæske til nebulisator, opløsning
teva b.v. - salbutamolsulfat - inhalationsvæske til nebulisator, opløsning - 1mg/ml
spiriva respimat 2,5 mikrogram inhalationsvæske, opløsning
paranova danmark a/s - tiotropium bromid - inhalationsvæske, opløsning - 2,5 mikrogram
spiriva respimat 2,5 mikrogram inhalationsvæske, opløsning
orifarm a/s - tiotropium bromid - inhalationsvæske, opløsning - 2,5 mikrogram
ventoline 1 mg/ml inhalationsvæske til nebulisator, opløsning
glaxosmithkline pharma a/s - salbutamolsulfat - inhalationsvæske til nebulisator, opløsning - 1 mg/ml
ventoline 5 mg/ml inhalationsvæske til nebulisator, opløsning
glaxosmithkline pharma a/s - salbutamolsulfat - inhalationsvæske til nebulisator, opløsning - 5 mg/ml
suspirinix 1 mg/ml inhalationsvæske til nebulisator, opløsning
2care4 aps - salbutamolsulfat - inhalationsvæske til nebulisator, opløsning - 1 mg/ml
buscopan 10 mg overtrukne tabletter
nordic prime aps - hyoscinbutylbromid - overtrukne tabletter - 10 mg
bumacor 20 mg/ml injektionsvæske, opløsning
macure pharma aps - hyoscinbutylbromid - injektionsvæske, opløsning - 20 mg/ml
airexar spiromax
teva b.v. - salmeterol, fluticasonpropionat - pulmonary disease, chronic obstructive; asthma - medicin for obstruktiv sygdomme, - airexar spiromax er indiceret til brug kun hos voksne i alderen 18 år og ældre. asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist. kronisk obstruktiv lungesygdom (kol)airexar spiromax er indiceret til symptomatisk behandling af patienter med kol med fev1.
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - medicin for obstruktiv sygdomme, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).